<DOC>
	<DOC>NCT00606866</DOC>
	<brief_summary>The purpose of this study is to determine maximum tumor shrinkage, time to progression, survival, drug concentration, and degree of skin toxicity.</brief_summary>
	<brief_title>MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically or cytologically confirmed metastatic clear cell renal cell cancer; At least one lesion that can be accurately measured in at least one dimension; Patients must not have been treated with prior antitimor kinase inhibitors or VEGF pathway inhibitors; Age 18 and older; ECOG performance status 02; Blood pressure higher than 140/90 on 2 separate occasions not more than 6 weeks prior to enrollment and not less than 24 hours apart; Normal organ function: total bilirubin less than upper limit of normal, AST less than 2.5 X upper limit of normal, creatinine less than 2.8 mg/dl; Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation; Ability to understand and the willingness to sign a written informed consent document. Chemotherapy or radiotherapy within 4 weeks prior to entering the study; Any other investigational agents; Known brain metastases; Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; Pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>renal, metastatic, carcinoma</keyword>
</DOC>